Marikki Laiho, MD, PhD
Disclosures: Royalty-Bluefield Innovations-Principal_Investigator-Sponsored research award and option agreement income.|Receipt of Intellectual Property Rights/Patent Holder-Johns Hopkins University-Principal_Investigator|Contracted Research-Bluefield Innovations-Principal_Investigator Other_Role
CV English 2p 11/95

Curriculum Vitae                            Marikki Laiho, M.D., Ph.D.

 

Curriculum vitae                                             June 1, 2020 

allekirjoitus

Name               Marikki K. Laiho, M.D., Ph.D.

 

DEMOGRAPHIC AND PERSONAL INFORMATION

 

Current appointment               Professor and Director

                            Vice Chair for Research

                                          Willard and Lillian Hackerman Professor in Radiation Oncology

Departments of Radiation Oncology and Molecular Radiation Sciences and Oncology

                            The Johns Hopkins University School of Medicine

 

Personal Data

Department of Radiation Oncology

The Johns Hopkins School of Medicine

1550 Orleans Street, Room 444

Baltimore, MD 21287

Tel: 410-502-9748

FAX: 410-502-2821

E-mail: mlaiho1@jhmi.edu

Education and Training

 

1980              Matriculation examination, Haukilahden lukio, Espoo, Finland

1983               Bachelor of Medicine, University of Helsinki, Helsinki, Finland

1986               Junior house officer, Clinics of Internal Medicine, Surgery and Children’s Hospital, Helsinki University Central Hospital, Helsinki

1987               Licentiate of Medicine (M.D.), University of Helsinki

1987               Internship, Helsinki Municipal Health Services, Helsinki             

1984-88               Doctor of Medical Science (Ph.D.), University of Helsinki, accepted with distinction

1988-89               Postdoctoral fellow, Department of Biochemistry, University of Massachusetts Medical Center, Worcester, MA, Laboratory of Joan Massagué, Ph.D.

1989-90               Research Associate, Cell Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY, Laboratory of Joan Massagué, Ph.D.

1991              Docent (Senior Lecturer/Reader), Cell Biology, University of Helsinki

2009              Leadership Development Program, Johns Hopkins Medicine, Johns Hopkins University

2014              Master Mentor Program, Johns Hopkins Medicine, Johns Hopkins University

Professional Experience

 

1983-87               Research and Teaching Assistant, Department of Virology, University of Helsinki

1988-90               Research Associate, Academy of Finland

1990-94               Research and Teaching Assistant, Department of Virology, University of Helsinki

1992-95               Junior Fellow, Academy of Finland

1996-03              Academy Research Fellow (Senior Fellow), Academy of Finland

2001-02              Acting Professor in Cancer Biology, Department of Pathology, University of Helsinki

2003              Senior Scientist, Academy of Finland

2004              Scientific Secretary, Research Council, Faculty of Medicine, University of Helsinki

2005-2012               Director, Biomedicum Imaging Unit, University of Helsinki

2005-2007              Research Professor, Foundation for the Finnish Cancer Institute

2006-2011              Professor in Molecular Cancer Medicine, University of Helsinki

2006-6/2007              Director, Molecular Cancer Biology Program, University of Helsinki

2006-8/2007              Coordinator, Helsinki Functional Imaging Center, Helsinki

8/2007-7/2008              Visiting Professor and Director, Division of Molecular Radiation Sciences, Department of Radiation Oncology, The Johns Hopkins University School of Medicine

7/2008-present              Professor and Director, Division of Molecular Radiation Sciences, Department of Radiation Oncology and Department of Oncology, The Johns Hopkins University School of Medicine

2008-              Member, SKCCC, Chemical Therapeutics Program

2008-               Member, Graduate Program in Cellular and Molecular Medicine, Johns Hopkins University

2009-               Member, Graduate Program in Pathobiology, Johns Hopkins University

2011-              Co-Director, SKCCC Developing Program on DNA Damage Biology

2012-               Co-Director, SKCCC Experimental Irradiators Core Facility

2016-              Professor in Pharmaceutical Cell and Molecular Biology  (part-time) Faculty of Pharmacy, University of Helsinki, Helsinki, Finland

2017-              Vice Chair for Research, Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine

2019-               Co-Director, Chemical and Structural Biology Program, SKCCC

 

PUBLICATIONS

                                                        Citations as of March 28, 2019

Peer-reviewed Original Research

1.              Saksela O, Laiho M, Keski-Oja J. Regulation of plasminogen activator activity in human fibroblastic cells by fibrosarcoma cell-derived factors. Cancer Res. 45: 2314-2319, 1985.                                           Citations:17

2.              Alitalo K, Saksela K, Winqvist R, Alitalo R, Keski-Oja J, Laiho M, Ilvonen M, Knuutila S, de la Chapelle A. Acute myelogenous leukemia with c-myc amplification and double minute chromosomes. Lancet 8463: 1035-1039, 1985.                            Citations:84

3.              Laiho M, Saksela O, Keski-Oja J. Transforming growth factor-ß alters plasminogen activator activity in human skin fibroblasts. Exp. Cell. Res. 164: 399-407, 1986.                                          Citations:111

4.              Keski-Oja J, Laiho M, Vartio T. Characterization of a novel gelatin-binding 21 kDa protein secreted by cultured adherent cells. Biochim. Biophys. Acta 882: 367-376, 1986.                                          Citations:8

5.              Laiho M, Saksela O, Andreasen PA, Keski-Oja J. Enhanced production and extracellular deposition of the endothelial type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-ß. J. Cell. Biol. 103: 2403-2410, 1986.                                          Citations:435

6.              Lund LR, Riccio A, Andreasen PA, Nielsen LS, Kristensen P, Laiho M, Saksela O, Blasi F, Danø K. Transforming growth factor-ß is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J. 5: 1281-1286, 1987.                             Citations:253

7.              Laiho M, Saksela O, Keski-Oja J. Transforming growth factor-ß-induction of type-1 plasminogen activator inhibitor: Pericellular deposition and sensitivity to exogenous urokinase. J. Biol. Chem. 262: 17467-17474, 1987.                            Citations:276

8.              Laiho M. Modulation of extracellular proteolytic activity and anchorage-independent growth of cultured cells by sarcoma cell-derived factors: Relationships to transforming growth factor-ß. Exp. Cell. Res. 176: 297-308, 1988.                            Citations:10

9.              Anklesaria P, Teixido J, Laiho M, Pierce J, Greenberger JS, Massagué J. Cell-cell adhesion mediated by binding of membrane-anchored transforming growth factor alpha to epidermal growth factor receptors promotes cell proliferation. Proc. Natl. Acad. Sci. USA 87: 3289-3293, 1990.                            Citations:254

10.              Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massagué J. Growth inhibition by TGF-ß linked to suppression of retinoblastoma protein phosphorylation. Cell 62: 175-185, 1990.                            Citations:840

11.               Laiho M, Weis FMB, Massagué J. Concomitant loss of transforming growth factor-ß receptor types I and II in TGF-ß-resistant cell mutants implicates both receptor types in signal transduction. J. Biol. Chem. 265: 18518-18524, 1990.                Citations:313

12.              Cheifetz S, Hernandez H, Laiho M, ten Tijke P, Iwata KK, Massagué J. Distinct transforming growth factor-ß (TGF-ß) receptor subsets as determinants of cellular responsiveness to three TGF-ß isoforms. J. Biol. Chem. 265: 20533-20538, 1990.                                          Citations:314

13.               Laiho M, Rönnstrand L, Heino J, DeCaprio JA, Ludlow JW, Livingston DM, Massagué J. Control of junB and extracellular matrix protein expression by transforming growth factor-ß1 is independent of SV40 T antigen sensitive growth inhibitory effects. Mol. Cell. Biol. 11: 972-978, 1991.                            Citations:107

14.               Laiho M, Weis FMB, Boyd FT, Ignotz RA, Massagué J. Responsiveness to transforming growth factor-ß restored by genetic complementation between cells defective in TGF-ß receptors I and II. J. Biol. Chem. 266: 9108-9112, 1991.                             Citations:244

15.              Zentella A, Weis FMB, Ralph DA, Laiho M, Massagué J. Early gene responses to transforming growth factor-ß in cells lacking RB function. Mol. Cell. Biol. 11: 4952-4958, 1991.                            Citations:116

16.              Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang XF, Massagué J. TGF-ß signals through a heteromeric protein kinase receptor complex. Cell 71: 1003-1014, 1992.                            Citations:1376

17.              Pitkänen K, Kivinen L, DeCaprio JA, Laiho M. Expression of the human retinoblastoma gene product in mouse fibroblasts: Effects on cell proliferation and susceptibility to transformation. Exp. Cell. Res. 207: 99-106, 1993.                            Citations:10

18.              Kivinen L, Pitkänen K, Laiho M. Human retinoblastoma gene product prevents c-Ha-ras oncogene mediated cellular transformation of mouse fibroblasts. Oncogene 8: 2703-2711, 1993.                            Citations:9

19.               ten Dijke P, Yamashita H, Ichijo H, Franzén P, Laiho M, Miyazono K, Heldin CH. Characterization of type I receptors for transforming growth factor-beta and activin. Science 264: 101-104, 1994.                            Citations:496

20.              Haapajärvi T, Kivinen L, Pitkänen K, Laiho M. Cell cycle dependent effects of UV-radiation on p53 expression and retinoblastoma protein phosphorylation. Oncogene 11: 151-159, 1995.                            Citations:42

21.               Kivinen L, Tiihonen E, Haapajärvi T, Laiho M. p21ras mediated decrease of the retinoblastoma protein in fibroblasts occurs through growth factor dependent mechanisms. Cell Growth Differ. 7: 1705-1712, 1996.                            Citations:3

22.              Haapajärvi T, Pitkänen K, Tsubari M, Laiho M. p53 transactivation and protein accumulation are independently regulated by UV light in different phases of the cell cycle. Mol. Cell. Biol. 17: 3074-3080, 1997.                            Citations:33

23.               Enholm B, Paavonen K, Ristimäki A, Kumar V, Klefström J, Kivinen L, Laiho M, Olofsson B, Joukov V, Eriksson U, Alitalo K. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNAs regulation by serum, growth factors, oncoproteins, and hypoxia. Oncogene 14: 2475-2483, 1997.                            Citations:367

24.              Tsubari M, Tiihonen E, Laiho M. Cloning and characterization of p10, an alternative spliced form of p15 CDK-inhibitor. Cancer Res. 57: 2966-2973, 1997.              Citations:26

25.               Pitkänen K, Haapajärvi T, Laiho M. UVC-induction of p53 activation and accumulation is dependent on cell cycle and pathways involving protein synthesis and phosphorylation. Oncogene 16: 459-469, 1998.                            Citations:17

26.               Haapajärvi T, Pitkänen K, Laiho M. Human melanoma cell line UV responses show independency of p53 function. Cell Growth Differ. 10: 163-171, 1999.               Citations:49

27.              Tsubari M, Taipale J, Tiihonen E, Keski-Oja J, Laiho M. Hepatocyte growth factor releases mink epithelial cells from transforming growth factor-ß1 induced growth arrest by restoring Cdk6 expression and cyclin E-associated Cdk2-activity. Mol. Cell. Biol. 19: 3654-3663, 1999.                            Citations:30

28.              Haapajärvi T, Kivinen L, Heiskanen A, des Bordes C, Datto MB, Wang XF, Laiho M. UV-radiation is a transcriptional inducer of p21Cip1/Waf1 cyclin kinase inhibitor in a p53 independent manner. Exp. Cell Res. 248: 272-279, 1999.                            Citations:57

29.               Kivinen L, Laiho M. Ras and mitogen-activated protein kinase-dependent and independent pathways in p21Cip1/Waf1 induction by FGF-2, PDGF and TGF-ß. Cell Growth Differ. 10: 621-628, 1999.                            Citations:33

30.              Kivinen L, Tsubari M, Haapajärvi T, Datto MB, Wang XF, Laiho M. Ras induces p21Cip1/Waf1 cyclin kinase inhibitor transcriptionally through Sp1-binding sites. Oncogene 18: 6252-6261, 1999.                             Citations:58

31.              Taipale M, Tiihonen E, Heiskanen A, Laiho M. Accumulation of a form of p27Kip1 not associated with Cdk-cyclin complexes in transforming growth factor-ß arrested Mv1Lu cells. Exp. Cell Res. 259: 107-116, 2000.                            Citations:3

32.              Zhang F, Taipale M, Heiskanen A, Laiho M. Ectopic expression of Cdk6 circumvents transforming growth factor-ß mediated growth inhibition. Oncogene 20: 5888-5896, 2001.                                          Citations:7

33.              Latonen L, Taya Y, Laiho M. UV-radiation induces dose-dependent regulation of p53 response and modulates p53-HMD2 interaction in human fibroblasts. Oncogene 20: 6784-6793, 2001.                            Citations:89

34.              Buzek J, Latonen L, Kurki S, Laiho M. Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277. Nucleic Acids Res. 30: 2340-2348, 2002.                             Citations:77

35.              Zhang F, Mönkkönen M, Roth S, Laiho M. Proteasomal activity modulates TGF-ß signaling in a gene-specific manner. FEBS Lett. 527: 58-62, 2002.                             Citations:15

36.              Zhang F, Mönkkönen M, Roth S, Laiho M. TGF-ß induced G1 cell cycle arrest requires the activity of the proteasome pathway. Exp. Cell. Res. 281: 190-196, 2002.               Citations:14

37.              Latonen L, Kurki S, Pitkänen K, Laiho M. p53 and MDM2 are regulated by PI-3-kinases on multiple levels under stress induced by UV-radiation and proteasome dysfunction. Cell. Signal. 15: 95-102, 2003.                            Citations:31

38.              Zhang F, Lundin, M, Ristimäki A, Heikkilä P, Lundin J, Isola J, Joensuu H, Laiho M. Ski-related novel protein N (SnoN), a negative controller of TGF-ß signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res. 63: 5005-5010, 2003.                                          Citations:72

39.              Gentile M, Latonen L, Laiho M. Cell cycle arrest and apoptosis provoked by UV radiation-induced DNA damage are transcriptionally highly divergent responses. Nucleic Acids Res. 31: 4779-4790, 2003.                            Citations:89

40.              Kurki S, Latonen L, Laiho M. Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization. J. Cell. Sci. 116: 3917-3925, 2003.                            Citations:71

41.              Kurki S, Peltonen K, Latonen L, Kiviharju T, Ojala PM, Meek D, Laiho M. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 5: 465-475, 2004.               Citations:283

42.              Vaque JP, Navascues J, Shiio Y, Laiho M, Ajenjo N, Mauleon I, Matallanas D, Crespo P, Leon J. Myc antagonizes Ras-mediated growth arrest in leukemia cells through the inhibition of the Ras-ERK-p21Cip1 pathway. J. Biol. Chem. 280: 1112-1122, 2005.              Citations:34

43.              von Willebrand M, Köhler K, Alanko T, Laiho M, Saksela, O. FGF-2 blocks TGF-ß1 –mediated suppression of Bcl-2 in normal melanocytes. Exp. Dermatol. 14: 202-208, 2005.              Citations:6

44.              Peltonen K, Kiviharju T, Järvinen P, Ra R, Laiho M. Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis. Pigment Cell Res. 18: 196-202, 2005.               Citations:29

45.              Laine H, Doetzlhofer A, Mantela J, Ylikoski J, Laiho M, Roussel M, Segil N, Pirvola U. p19Ink4d and p21Cip1 collaborate to maintain the postmitotic state of auditory hair cells, their codeletion leading to DNA damage and p53-mediated apoptosis. J. Neurosci. 27: 1434-1444, 2007.              Citations:72

46.              Sarek G, Kurki S, Enbäck J, Iotzova G, Haas J, Laakkonen P, Laiho M, Ojala PM. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J. Clin. Invest. 117: 1019-1028, 2007.              Citations:98

47.              Kiviharju-af Hällström T, Jäämaa S, Mönkkönen M, Peltonen K, Andersson LC, Medema R, Peehl D, Laiho M. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc. Natl. Acad. Sci. USA 104: 7211-7216, 2007.

                            Citations:48

48.              Koopal S, Furuhjelm JH, Järviluoma A, Jäämaa S, Pyakurel P, Pussinen C, Wirzenius M, Biberfeld P, Alitalo K, Laiho M, Ojala PM. Viral oncogene-induced DNA damage response is activated in Kaposi’s sarcoma tumorigenesis. PLoS Pathog. 3: 1348-1360, 2007.

                                                                                                                                          Citations:75

49.              Latonen L, Järvinen P, Laiho M. Cytoskeleton-interacting LIM-domain protein CRP1 suppresses cell proliferation and protects from stress-induced cell death. Exp. Cell Res. 314: 738-747, 2008.                            Citations:16

50.               Band AM, Björklund M, Laiho M. The phosphatidylinositol 3-kinase/Akt pathway regulates transforming growth factor-ß signaling by de-stabilizing Ski and inducing Smad7. J. Biol. Chem. 284: 35441-35449, 2009.              Citations:20

51.               Latonen L, Järvinen PM, Suomela, S, Moore HM, Saarialho-Kere U, Laiho M. Ultraviolet B radiation regulates cysteine rich protein 1 in human keratinocytes. Photoderm. Photoimm. Photomed. 26: 70-77, 2010.               Citations:7

52.              Björklund MA, Vaahtomeri K, Peltonen K, Viollet B, Mäkelä TP, Band AM, Laiho M. Non-CDK-bound p27 (p27NCDK) is a marker for cell stress and is regulated through the Akt/PKB and AMPK-kinase pathways. Exp. Cell Res. 316: 762-774, 2010.              Citations:5

53.               Sulg M, Kirjavainen A, Pajusola K, Ylikoski J, Bueler H, Laiho M, Pirvola U. Differential sensitivity of the inner ear sensory cell populations to forced cell cycle re-entry and p53 induction. J. Neurochem. 112: 1513-1526, 2010.              Citations:8

54.              Sarek G, Järviluoma A, Moore HM, Tojkander S, Vartia S, Biberfeld, P, *Laiho M, *Ojala P. Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency. PLoS Pathog. 6:  e1000818, 2010.  *equal contribution.              Citations:46

55.               Jäämaa S, af Hällström TM, Sankila A, Rantanen V, Koistinen H, Stenman U, Zhang Z, Yang Z, De Marzo A, Taari K, Ruutu M, Andersson LC, Laiho M. DNA damage recognition via activated ATM and p53 pathway in non-proliferating human prostate tissue. Cancer Res. 70: 8630-8641, 2010.               Citations:40

56.              Latonen L, Moore HM, Bai B, Jäämaa S, Laiho M. Proteasome inhibitors induce nucleolar aggregation of proteasome target proteins and polyadenylated RNA by altering ubiquitin availability. Oncogene 30: 790-805, 2011.               Citations:57

57.              Peltonen K, Colis L, Liu H, Jäämaa S, Moore HM, Enbäck J, Laakkonen P, Vaahtokari A, Jones RJ, af Hällström TM, Laiho M. Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. PLoS One 5(9): e12996, 2010.              Citations:48

58.              Ni X, Zhang Y, Ribas J, Chowdhury WM, Castanares M, Zhang Z, Laiho M, DeWeese TL, Lupold SE. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J. Clin. Invest. 121: 2383-2390, 2011.               Citations:96

59.               Moore HM, Bai B, Boisvert FM, Latonen L, Rantanen V, Simpson JC, Pepperkok R, Lamond AI, Laiho M. Quantitative proteomics and dynamic imaging of the nucleolus reveals distinct responses to UV and ionizing radiation. Mol. Cell. Proteomics 10(10):M111.009241-15, 2011.               Citations:36

60.              Järvinen PM, Myllärniemi M, Liu H, Moore HM, Latonen L, Leppäranta O, Koli K, Salmenkivi K, Band A, Laiho M. Cysteine-rich protein 1 is regulated by transforming growth factor-ß1 and expressed in lung fibrosis. J. Cell Physiol. 227(6): 2605-2612, 2012.

                            Citations:9

61.              Zhang Z, Yang Z, Jäämaa S, Liu H, Pellakuru LG, Iwata T, af Hällström TM, De Marzo AM, Laiho M. Differential epithelium DNA damage response to ATM and DNA-PK pathway inhibition in human prostate tissue culture. Cell Cycle 10: 3545-3553, 2011.              Citations:15

62.              Jäämaa S, Sankila A, Rantanen V, Peltonen K, Järvinen P, af Hällström TM, Ruutu M, Taari K, Andersson LC, Laiho M.  Contrasting DNA damage checkpoint responses in epithelium of human seminal vesicle and prostate. Prostate 72(10): 1060-1070, 2012.               Citations:2

63.              Band AM, Laiho M. SnoN oncoprotein enhances estrogen receptor α transcriptional activity. Cell. Signal. 24(4): 922-930, 2012.               Citations:8

64.              Zhu L, Jäämaa S, af Hällström TM, Laiho M, Sankila A, Nordling S, Stenman UH, Koistinen H. PSA forms complexes with a1-antichymotrypsin in the prostate. Prostate 73(2): 219-226, 2012.              Citations:10

65.              Bai B, Laiho M. Efficient sequential recovery of nucleolar macromolecular components. Proteomics 12(19-20): 3044-3048, 2012.              Citations:6

66.              Moore HM, Bai B, Matilainen O, Colis L, Peltonen K, Laiho M. Proteasome activity influences UV-mediated subnuclear localization changes of NPM. PLoS One 8(3): e59096, 2013.              Citations:6

67.              Bai B, Moore HM, Laiho M. CRM1 and its ribosome export adaptor NMD3 localize to the nucleolus and affect ribosomal RNA synthesis. Nucleus 4(4): 315-325, 2013.               Citations:16

68.              af Hällström TM, Zhao H, Tian J, Rantanen V, Reese SW, Nolley R, Laiho M, Peehl DM. A tissue graft model of DNA damage response in the normal and malignant human prostate. J. Urology 191(3): 842-849, 2014.               Citations:2

69.              Peltonen K, Colis L, Liu H, Trivedi R, Moubarek MS, Moore HM, Bai B, Rudek MA, Bieberich CJ, Laiho M. A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell 25: 77-90, 2014.               Citations:86

70.              Bai B, Liu H, Laiho M. Small RNA expression and deep sequencing analyses of the nucleolus reveal the presence of nucleolus-associated microRNAs. FEBS Open Bio 4: 441-449, 2014.               Citations:23

71.              Laos M, Anttonen T, Kirjavainen A, af Hällström T, Laiho M, Pirvola U. DNA damage signaling regulates age-dependent proliferative capacity of quiescent inner ear supporting cells. Aging 6(6): 496-510, 2014.               Citations:7

72.              Colis L, Ernst G, Sanders S, Liu H, Sirajuddin P, Peltonen K, DePasquale M, Barrow JC, Laiho M. Design, synthesis and structure-activity relationships of pyridoquinazoline-carboxamides as RNA polymerase I inhibitors. J. Med. Chem. 57: 4950-4961, 2014. Citations:9

73.              Colis L, Peltonen K, Sirajuddin P, Liu H, Sanders S, Ernst G, Barrow JC, Laiho M. DNA intercalator BMH-21 inhibits RNA polymerase I independent of DNA damage response. Oncotarget 5(12): 4361-4369, 2014.               Citations:18

74.              Bai B, Yegnasubramanian S, Wheelan SJ, Laiho M. RNA-seq of the nucleolus reveals abundant SNORD44-derived small RNAs. PLoS One 9(9): e107519, 2014.               Citations:11

75.              Peltonen K, Colis L, Liu H, Jäämaa S, Zhang Z, af Hällström T, Moore HM, Sirajuddin P, Laiho M. Small molecule BMH-compounds that inhibit RNA polymerase I and cause nucleolar stress. Mol. Cancer Ther. 13(11): 2537-2546, 2014.               Citations:18

76.              Balistreri G, Viiliäinen J, Turunen M, Lyly L, Rantala J, Ojala K, Diaz R, Sarek G, Teesalu M, Denisova O, Peltonen K, Julkunen I, Varjosalo M, Kainov D, Kallioniemi O, Laiho M, Taipale J, Hautaniemi S, Ojala PM. Oncogenic Herpesvirus utilizes stress-induced cell cycle checkpoints for efficient lytic replication. PLoS Pathogens 12(2):e1005424, 2016. Citations:13

77.              Kara B, Koroglu C, Peltonen K, Steinberg RC, Maras Genç H, Hölttä-Vuori M, Güven A, Kanerva K, Kotil T, Solakoğlu S, Zhou Y, Olkkonen VM, Ikonen E, Laiho M, Tolun A. Severe neurodegenerative disease in brothers with homozygous mutation in POLR1A. Eur. J. Hum. Genet. 25(3): 315-323, 2017.               Citations:7

78.              Guner G, Sirajuddin P, Zheng Q, Bai B, Brodie A, Liu H, af Hällström T, Kulac I, Laiho M*, De Marzo AM*. Novel assay to detect RNA polymerase I activity in vivo. Mol. Cancer Res. 15(5): 577-584, 2017. *Corresponding authors. Citations:3

79.              Kilanczyk E, Andres K, Hallgren J, Laiho M, Whittemore SR, Hetman M. Pharmacological inhibition of spinal cord injury-stimulated ribosomal biogenesis does not affect locomotor outcome. Neurosci. Lett. 642: 153-157, 2017.               Citations:1

80.              Wei T, Najmi SM, Liu H, Peltonen K, Kucerova A, Schneider DA, Laiho M. Small-molecule Targeting of RNA Polymerase I Activates a Novel, Conserved Transcription Elongation Checkpoint. Cell Reports 23: 404-414, 2018.               Citations:2

81.              Shah AA, Laiho M, Rosen A, Casciola-Rosen L. Scleroderma patients with antibodies against the large subunits of both RNA polymerases-I and -III are protected against cancer. Arthritis Rheumatol. 71(9): 1571-1579, 2019.

82.               Low JI*, Sirajuddin P*, Moubarek M, Agarwal S, Rege A, Liu H, Yang Z, De Marzo AM, Bieberich C, Laiho M. Effective targeting of RNA polymerase I in treatment-resistant prostate cancer. The Prostate 79(16):1837-1851, 2019.

83.               mäläinen RH, Landoni JC, Ahlqvist KJ, Goffart S, Ryytty S, Rahman MO, Brilhante V, Icay K, Hautaniemi S, Wang L, Laiho M, Suomalainen A. Defects in mtDNA replication challenge nuclear genome stability through nucleotide depletion and provide a unifying mechanism for mouse progerias. Nature Metabolism 1: 958-965, 2019.

84.              Low JY, Brennen WN, Meeker AK, Ikonen E, Simons BW, Laiho M. Stromal CAVIN1 controls prostate cancer microenvironment and metastasis by modulating lipid distribution and inflammatory signaling. Mol. Cancer Res. In press 2020.

 

Peer-reviewed Review Articles

1.              Keski-Oja J, Laiho M, Alitalo K. Syöpäsolu kiihdyttää kasvuaan. Tiede 2000 6: 18-21, 1986. (Cancer cell growth control)

2.              Keski-Oja J, Laiho M. Kasvutekijät ja kudosvaurioiden paraneminen. Duodecim 104: 1220-1230, 1988. (Growth factors and wound healing)

3.              Laiho M, Keski-Oja J. Growth factors in the regulation of pericellular proteolysis of cultured cells. Cancer Res. 49: 2533-2553, 1989.              Citations:360

4.              Keski-Oja J, Lohi J, Laiho M. Transforming growth factor-ß:s as modulators of pericellular proteolytic events. Cytotechnology 2: 317-332, 1989.               Citations:1

5.              Saksela O, Laiho M. Kasvutekijät ja soluväliaine. Duodecim 106: 297-306, 1990. (Growth factors and extracellular matrix)

6.              Boyd FT, Cheifetz S, Andres J, Laiho M, Massagué J. TGF-ß receptors and binding proteoglycans. J. Cell Sci. Suppl. 13: 131-138, 1990.              Citations:31

7.              Keski-Oja J, Koli K, Lohi J, Laiho M. Growth factors in the regulation of plasminogen-plasmin system in tumor cells. Semin. Thromb. Hemost. 17: 231-239, 1991.              Citations:46

8.              Laiho M, Alitalo K. Kasvurajoitegeenien muutokset syövän syntymekanismina. Duodecim 107: 1680-1691, 1991. (Tumor suppressor genes)

9.              Laiho M, Keski-Oja J. Transforming growth factors-ß as regulators of cellular growth and phenotype. Crit. Rev. Oncog. 3: 1-26, 1992.              Citations:75

10.              Pitkänen K, Tsubari M, Kivinen L, Laiho M. Kasvurajoitegeenit, solusykli ja syöpä. Solubiologi 12: 27-33, 1993. (Tumor suppressor genes, cell cycle and cancer)

11.              Latonen L, Laiho M. p53 perimämme vartijana. Solubiologi 17: 15-19, 1999. (p53 as a guardian against genotoxic stress)

12.              Laiho M. Miten syöpä syntyy. Duodecim 118: 1751-1758, 2002. (Genesis of cancer)             

13.              Laiho M, Latonen L. Cell cycle control, DNA damage checkpoints and cancer. Annals Med. 35: 391-397, 2003.               Citations:32

14.              Zhang F, Laiho M. On and Off: Proteasome and TGF-ß signaling. Exp. Cell Res. 291: 275-281, 2003.              Citations:52

15.              Kurki S, Peltonen K, Laiho M. Nucleophosmin, HDM2 and p53 - players in UV damage incited nucleolar stress response. Cell Cycle 3: 976-979, 2004.              Citations:55

16.              Laiho M. Syövän molekyylitason muutokset. Focus Oncologiae 23-26, 2005. (Molecular changes in cancer)

17.              Latonen L, Laiho M. Cellular UV damage responses - functions of tumor suppressor p53. BBA Reviews in Cancer 1755: 71-89, 2005.              Citations:136

18.              Laiho M, Latonen L. Solujen ikääntyminen on taistelua syöpää vastaan. (Senescence as a barrier against cancer). Tiede 3: 20-25, 2008.

19.              af Hällström T, Laiho M. Genetic changes and DNA damage responses in the prostate. Prostate 68: 902-918, 2008.                                                                              Citations:23

20.              Band AM, Laiho M. Crosstalk of TGF-β and estrogen receptor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia 16: 109-115, 2011.               Citations:43

21. Järvinen PM, Laiho M. LIM-domain proteins in transforming growth factor-beta induced epithelial-to-mesenchymal transition and myofibroblast differentiation. Cell. Signal. 24(4): 819-825, 2012.               Citations:18

22.              Jäämaa S, Laiho M. Maintenance of genomic integrity after DNA double strand breaks in the human prostate and seminal vesicle epithelium: the best and the worst. Mol. Oncol. 6(5): 473-483, 2012.               Citations:4

 

Editorials

1.              Laiho M. Solusyklin jarrut - uusia kasvunrajoitegeenejä? Duodecim 110: 12-14, 1994. (Cellular brakes - novel tumor suppressor genes?)

2.              Latonen L, Laiho M. Kemian Nobelin palkinto proteiinien tuhoamisreitin selvittäjille. Duodecim 120: 2868-2871, 2004. (Nobel Prize in Chemistry to discoverers of the protein destruction pathway)

3.              Laiho M, Saksela E. Perimän vauriot, vanheneminen ja syöpä – erottamaton triadi. (DNA damage, senescence and cancer – an uncoupled triad). Duodecim 123: 1535-1536, 2007.

4.              Syrjäkari H, Laiho M. Välkettä syvyyksistä – kemian Nobelin palkinto vihreän fluoresoivan proteiinin keksijöille. Duodecim 124: 2599-2601, 2008. (Nobel Prize in Chemistry to the discovery of green fluoresecent protein)

5.              Laiho M. Syövän tutkimus Suomessa. (Cancer research in Finland). Duodecim 125: 5-6, 2009.

6.              Resar LMS, Jaffee EM, Armanios M, Jackson S, Azad NS, Horton MR, Kaplan MJ, Laiho M, Maus MV, Sumner CJ, Wheelan SJ, Wills-Karp M. Equity and diversity in academic medicine: a perspective from the JCI editors. J. Clin. Invest. 129(10): 3974-3977, 2019.

 

Book chapters, monographs

1.              Laiho M. Transforming growth factor-ß in the regulation of extracellular proteolysis of cultured cells. University of Helsinki, Helsinki. ISBN 951-99925-6-1 71 pages, 1988.

2.              Massagué J, Pandiella A, Laiho M. Growth stimulation by cell to cell contact and growth suppression: Two aspects of the biology of transforming growth factors. In: Cell to Cell Interaction, Karger, Basel, Eds. Burger MM, Sordat B, Zinkernagel RM, pp. 122-142, 1990.              Citations:3

3.              Massagué J, Heino J, Laiho M. Mechanisms of TGF-ß action. In: Clinical applications of TGF-ß. Wiley, Chichester, CIBA Foundation Symposium 157, pp. 51-65, 1990.              Citations:31

4.              Massagué J, Cheifetz S, Laiho M, Ralph DA, Weis FMB, Zentella A. Transforming growth factor-ß. In: Tumour suppressor genes, the cell cycle and cancer. Ed. A. Levine, Cancer Surveys, vol 12, Imperial Cancer Research Fund, pp. 81-103, 1992.              Citations:292

5.              Laiho M. Aberrations of DNA damage response and checkpoints in cancer. In: Apoptosis, Cell Signaling and Human Diseases: Molecular Mechanisms. Ed R. Srivastava, Humana Press, 119-136, 2006.

6.              Band A, Laiho M. Proteasome in the Control of TGF-ß Signaling During Development and Cancer. In: Transforming growth factor-beta in cancer therapy. Ed. S. Jakowlew, Humana Press, Totowa, NJ, pp. 243-257, 2008.               Citations:4

7.              Bai B, Laiho M. Sequential Recovery of the Macromolecular Components of the Nucleolus. Methods in Molecular Biology, In: The Nucleus – second edition, Ed. R. Hancock, Springer/Humana Press, 1228: 43-51, 2015.                                                         Citations:1

8.              Bai B, Laiho M. Deep Sequencing Analysis of Nucleolar Small RNAs: RNA Isolation and Library Preparation. In: The Nucleolus: Methods and Protocols, Ed. A. Nemeth, Springer/Humana Press, 1455: 231-241, 2016.

9.              Bai B, Laiho M. Deep Sequencing Analysis of Nucleolar Small RNAs: Bioinformatics. In: The Nucleolus: Methods and Protocols, Ed. A. Nemeth, Springer/Humana Press, 1455: 243-248, 2016.

Books

  1.       Laiho M, Lappalainen M, Saxén L. Molecular biology and biotechnology research in Finland. ISBN 951-715-268-X, 241 pages, 1996.
  2.     DeWeese TL, Laiho M. (Editors) Molecular Determinants of Radiation Response. Springer, New York, NY. ISBN 978-1-4419-8043-4, 276 pages, 2011. 

 

Complete List of Published Work in MyBibliography at NCBI: http://www.ncbi.nlm.nih.gov/sites/myncbi/1fQ2cEVU_MyQn/bibliography/47007621/public/?sort=date&direction=ascending

March 2019: 103 peer-reviewed publications in the Web of Science with 8897 total citations. H-index 42.

 

FUNDING

Extramural funding

 

Current:

 

12/17/2017-12/316/2020 Developing of A First-in-Class RNA Polymerase I Inhibitor for Cancer Therapy

Blue One Biosciences LLC

$9,227,840

PI: Laiho

Role: PI, 20% effort

To develop and optimize inhibitors of RNA polymerase I and conduct analyses for patient selection strategies.

 

08/01/2017-07/31/2021 Mechanistic analyses of a novel RNA polymerase I transcription checkpoint

NIH R01 GM121404

$1,445,424 total project direct costs

PI: Laiho

Role: PI, 25% effort

To define novel cellular control networks governing Pol I activity.

 

09/01/17-09/30/20 A New Paradigm Coupling Stromal Microenvironment to Prostate Cancer Lipid and RNA Synthesis with Therapeutic Application

DoD CDRMP PCRP IDA

$596,157 direct costs

PI: Laiho

Role: PI, 25% effort

To study role of PTRF as a factors that connects lipid metabolism to rRNA synthesis, and test the applicability of lipid metabolism and rRNA synthesis inhibitors in prostate cancer preclinical models.

 

 

Previous:

 

09/01/15-08/31/19 Academy of Finland (288364)                                         

RNA polymerase I regulatory functions of a novel small molecule anticancer compound

PI: Laiho

This grant studies the impact of BMH-21 on the structural and functional alterations of the nucleolus using electron microscopy and proteomics analysis.

 

01/01/16-12/31/18 R21 CA193637-01 Chemogenomic Profiling of a Novel RNA Polymerase I Inhibitor

$275,000 direct costs over two years

PI: Laiho

Role: PI, 10% effort

The application pertains an exploratory study on chemogenomic synthetic lethality screens that exploit cancer cell lethality that arises from inhibition of Pol I transcription.

 

01/01/15 ­ 03/31/18 Development of first-in-kind systemic cancer therapy targeting a major cancer deregulated process

              $100,000 direct costs, $148,800 Stage 2 funding

Harrington Scholar-Innovator Award

PI: Laiho

              Role: PI, 5% effort

The aims of the project are: To optimize BMH-21-like molecules for clinical candidate selection and to establish efficacy of the new BMH-21 analogs and pharmacodynamic markers for on-target responses.

 

01/01/14-12/31/18 R01 CA172069 Dual High-Throughput Imaging Screen for Nucleolar Integrity and RNA Transcription

              $250,000

              PI: Laiho

              Role: PI, 25% effort

 

07/01/16-06/30/17 Development of A Clinical Lead Molecule for RNA Polymerase I

Cigarette Restitution Fund             

$50,000 direct costs

PI: Laiho

Role: PI, 1% effort

To test the activity and applicability of new Pol I inhibitory lead molecules.

 

09/01/16-08/31/17 Lipids Meet RNA Production – A New Paradigm Coupling Stromal Microenvironment to Prostate Cancer Energy Metabolism

Walsh Prostate Cancer Fund

$100,000 direct costs

PI: Laiho

Role: PI, 1% effort

To establish methods and models to study stroma-tumor interactions mediated by a Pol I regulatory protein.

 

10/01/14 ­ 07/31/17 Systemic Treatment For Metastatic Prostate Cancer By A Novel Small

Molecule Targeting RNA Polymerase I

PCF Prostate Cancer Foundation

$500,000 direct costs initial year

PI: Laiho

Role: PI, 5% effort

Demonstrate the unique positioning of a novel anticancer small molecule in co-targeting of RNA polymerase I and AR and its efficacy in treatment of metastatic prostate cancer

 

04/01/15-03/31/17 Nucleolus: A novel paradigm for PARP1/2 functions and clinical application Allegheny Health Network-Johns Hopkins Cancer Research Fund

              $100,000 direct costs initial year

PI: Laiho

              Role: PI, 5% effort

The aims of the project are: Aim 1. Define nucleolar PARP1 and PARP2 functions in rRNA biogenesis. Aim 2. Examine synergism by inhibitors of Pol I and PARP1/2.

 

08/31/11-07/31/15 Academy of Finland (251307)

              Mechanisms of action of a novel DNA targeting small-molecule compound

              This grant investigates the DNA binding interactions a novel compound.

Role: Principal Investigator

 

07/15/13-04/14/14 A Novel Cancer Targeting Agent with Special Relevance in Castration-Resistant Prostate Cancer

              Maryland Technology Development Corporation

              $125,000

              PI: Laiho

              Role: PI, 10% effort

 

04/01/12-08/31/14 RNA Polymerase I Inhibition as a Strategy to Curb Prostate Cancer

              Patrick C. Walsh Prostate Cancer Research Fund

              $75,000

              PI: Laiho

                            Role: PI, 10% effort: share $60,000

 

09/01/11-31/08/12 Prostate Cancer SPORE (5P50CA58236) Developmental Project (Nelson) Novel small-molecule androgen receptor regulators

The major goal is study how identified lead compounds affect androgen signaling pathway.

Role: Principal Investigator

 

CLINICAL ACTIVITIES

Certification

 

1993              Licensed physician, National Board of Medicolegal Affairs, Finland

Service responsibilities

 

2007              Committee member, Cardiovascular and Metabolic Pharmacology Selection Committee

                           

EDUCATIONAL ACTIVITIES

Teaching

Teaching: Classroom

1983-90               Basic and clinical virology for medical and dentistry students, Teaching assistant, University of Helsinki.

1998               Problem-oriented learning for medical students, Scientific consultant, University of Helsinki.

1998-2007 Molecular and cancer biology course for medical students, Lecturer, University of Helsinki. 

 

Teaching: Workshops and seminars

1990,93                             Molecular Biology of Cell Growth, Differentiation and Cancer, University of Helsinki

1992               Basics of Cell Biology, University of Helsinki

1994               Cell Growth and Differentiation, University of Oulu

1997               Regulation of Gene Expression, Biocenter Oulu Graduate School, University of Oulu

1998               Methods in Cell Biology II,  Helsinki Biomedical Graduate School, University of Helsinki

1999               Science Fair, Medical Faculty of Helsinki. December 12, 1999. “Cell cycle control and DNA damage repair”.

2000               Clinical Molecular Pathology and Cancer, University of Helsinki. May 18-19, 2000. “p53 mutations and their clinical significance”.

2000               IMT Summer School in Molecular Biology, University of Tampere. August 16-24, 2000. “Cell cycle regulation by transforming growth factor-ß”.

2000              Apoptosis: From Molecular Mechanisms to Therapeutic Applications. Helsinki Biomedical Graduate School, University of Helsinki. September 4-7, 2000. ”p53-mediated cell death”.

2003               Murikka Summer School, Institute of Medical Technology, University of Tampere. Cancer, DNA instability and the Cell Cycle. August 8-10, 2003. “Comparative genomic analysis of cell arrest/death pathways induced by UV damage”.

2004               Advanced Molecular Biology, Helsinki Biomedical Graduate School, University of Helsinki. May 3-6, 2004. “The proteasome-ubiquitin system”.

2005               Biocentrum Helsinki Summer School. “p53 and DNA damage responses”.

2006               Biocentrum Helsinki Summer School. “p53 and DNA damage responses”.

2007              GSBM Course on Cancer Biology. December 11, 2007. Cellular DNA damage response and Cancer.

2014              Foundation for Advanced Education in the Sciences, Bethesda, NIH. November 7, 2014. “RNA-seq of the small RNAs in the nucleolus”.

2015              Foundation for Advanced Education in the Sciences, Bethesda, NIH. March 20, 2015. “RNA-seq of the small RNAs in the nucleolus”.

2015              Foundation for Advanced Education in the Sciences, Bethesda, NIH. August 7, 2015. “RNA-seq of the small RNAs in the nucleolus”.

2015              Foundation for Advanced Education in the Sciences, Bethesda, NIH. November 18, 2015. “RNA-seq of the small RNAs in the nucleolus”.

2016              Foundation for Advanced Education in the Sciences, Bethesda, NIH. March 16, 2016. “RNA-seq of the small RNAs in the nucleolus”.

2016              Foundation for Advanced Education in the Sciences, Bethesda, NIH. August 3, 2016. “RNA-seq of the small RNAs in the nucleolus”.

2016              Foundation for Advanced Education in the Sciences, Bethesda, NIH. November 16, 2016. “RNA-seq of the small RNAs in the nucleolus”.

 

 

Teaching: Organization of graduate student courses

1995              Practical training course in Essentials of Gene Technology, University of Helsinki, Finland

2002              Advanced Course on Molecular Biology of Cancer, University of Helsinki, Finland

2004              Applications of flow cytometry, University of Helsinki, Finland

2010-              Genomic Instability in Human Disease, CMM ME:810.716, Johns Hopkins University

Mentoring

Mentoring: Supervision of M.Sc./Ph.D. theses

 

Name              Dates               Degree              Present Position

Kimmo Pitkänen               1991-99               Ph.D.              Director, Helsinki Biobank

Tarja Mälkönen               1993-99              MD.,Ph.D.               (Accepted with distinction) Chief Attending, Dermatology, Helsinki and Uusimaa District Hospital, Helsinki

Laura Kivinen               1993-99               MD.,Ph.D.              Chief Attending, Internal Medicine, Helsinki and Uusimaa District Hospital, Espoo

Minna Taipale               1993-99               Ph.D.              Senior Researcher, Cambrige University, UK

Fan Zhang               2000-03               Ph.D.              Post-doctoral fellow, University of British

                                          Columbia

Leena Latonen               1998-03              Ph.D.               Post-doctoral fellow, University of Tampere

Sari Tojkander              2000-07               Ph.D.              (Accepted with distinction) Academy Fellow,

                                          University of Helsinki

Taija af Hällström              2003-07              Ph.D.              Senior Researcher, Orion, Espoo

Päivi Järvinen               2001-11              Ph.D.              Post-doctoral fellow, LMU Klinikum, Munchen

Mia Björklund               2001-20              Ph.D.              Manager, Finnish Red Cross

Sari Jäämaa              2001-11              M.D.,Ph.D.              Maternity leave

Rishi Trivedi              2011-13              M.Sc.              MD/PhD candidate, University of Louisiana Medical School

Henna M. Moore              2005-13              Ph.D.              Post-doctoral fellow, University of Helsinki

Jhanvi Patel              2013-14              M.Sc.              Research Program Assistant, Johns Hopkins University SON

Karita Peltonen              2001-14              Ph.D.              Research Manager, University of Helsinki

Brittany Ford              2018-              Ph.D. candidate University of Helsinki

Stephanie Pitts              2018-              Ph.D. candidate Johns Hopkins University

Mentoring: Post-doctoral

 

Name              Dates               Degree              Present Position

Stina Roth              2000-02              Ph.D.             

Jiri Buzek              1999-01              Ph.D.

Massimiliano Gentile              2002-03              Ph.D.              Informatics Director, Blueprint Genetics, Helsinki

Runar Ra              2003-05              Ph.D.             

Arja Band              2003-11              Ph.D.              Senior postdoctoral fellow, University of Helsinki

Laureen Colis              2007-13              Ph.D.              Scientist, Spark Therapeutics, Philadelphia, PA

Bayoan Bai              2008-13              Ph.D.              Postdoctoral fellow, University of Oslo

Zhiming Yang              2008-11              M.D., Ph.D.              Staff Pathologist, PathMD, Beverly Hills, CA

Zhewei Zhang              2008-10              M.D.              Attending Surgeon, Zhejiang University, Zhejiang

Paul Sirajuddin              2013-16              Ph.D.              Scientist, Cepheid, Sunnyvale, CA

Ting Wei              2013-              Ph.D.              Postdoctoral fellow, University of Helsinki

Jin-Yih Low              2017-20              Ph.D.              Staff, Fred Hutchinson Cancer Research Center

Asma Begum              2018-              Ph.D.              Research Associate, Johns Hopkins University

Wenjun Fan              2018-              Ph.D.              Postdoctoral fellow, Johns Hopkins University

Mentoring: thesis committees (member)

 

Name              Dates               Degree              University

Tiina Santonen              1995-99               Ph.D.              University of Turku

Juha Saharinen               1997-99               Ph.D.              University of Helsinki

Anneli Hotti               1997-00               Ph.D.              University of Helsinki

Anne West              1998-00               Ph.D.              University of Turku

Lila Pirkkala               1998-00               Ph.D.              University of Turku

Arno Pihlak               1998-00               Ph.D.              University of Helsinki

Marika Kärkkäinen               1998-01               Ph.D.              University of Helsinki

Päivi Joki-Korpela               1998-01               Ph.D.              University of Turku

Miina Weckroth               1998-02               M.D.,Ph.D.              University of Helsinki

Tea Vallenius               1999-03               M.D.,Ph.D.               University of Helsinki

Marika Häkli                2000-05               Ph.D.               University of Helsinki

Annika Järviluoma               2004-07               Ph.D.              University of Helsinki

Maria Wirzenius               2004-07               Ph.D.              University of Helsinki

Taru Muranen               2004-07               Ph.D.              University of Helsinki

Helka Parviainen               2004-11               M.D.              University of Helsinki

Mira Heinonen               2005-11               Ph.D.              University of Helsinki

Camilla Norrmén               2005-08               Ph.D.              University of Helsinki

Yuexi Gu              2010-15              Ph.D.              University of Helsinki

Susan Stanley              2013-15              Ph.D.              Johns Hopkins University

Alexandra Mims              2013-17               Ph.D.              Johns Hopkins University

Ruchama Steinberg              2017-20              Ph.D. candidate Johns Hopkins University

Dimitri Tschelenchuk              2018-              Ph.D. candidate Johns Hopkins University

Pre-examiner of doctoral dissertations

 

Name              Date               Degree              Field of study/University             

Päivi Miettinen                             1993              M.D.,Ph.D.              developmental biology, University of Helsinki 

Anna-Maija Partanen              1993              D.Ds.,Ph.D.               developmental biology, University of Helsinki

Sirpa Leppä                            1994              M.D.,Ph.D.              cell and molecular biology, University of Turku

Tapio Kesti                            1994              Ph.D.              molecular biology, University of Oulu

Katri Pajusola                            1995               Ph.D.              molecular cancer biology, University of Helsinki

Anne Vaahtokari               1996              Ph.D.               developmental biology, University of Helsinki

Mika Rämet                             1998               M.D.,Ph.D.              toxicology/ cell biology, University of Oulu

Hesham Attalla                            1998              M.D.,Ph.D.               cell biology/ endocrinology, University of Helsinki

Maarit Bärlund                            1999               M.D.,Ph.D.              cancer genetics, University of Tampere

Lila Pirkkala                            2000              Ph.D.              cell/ molecular biology, University of Turku

Anneli Hotti                            2000              Ph.D.               cell/ molecular biology, University of Helsinki

Niina Reunanen                            2000              M.D.,Ph.D.              cell/ molecular biology, University of Turku

Päivi Joki-Korpela              2001              M.D.,Ph.D.              virology, University of Turku

Minna Mäkiniemi               2001              Ph.D.              biochemistry/molecular biology, University of Oulu

Lea Pylkkänen                            2002              Ph.D.              genetics and toxicology, University of Joensuu

Pekka Taimen                            2004              M.D.,Ph.D.               cell/molecular biology, University of Turku

Pia Nyberg                            2005              Ph.D.              cell/molecular biology, University of Oulu

Teija Aho                             2005              Ph.D.              cell/molecular biology, University of Turku

Katri Pylkäs                            2007              Ph.D.              cancer genetics, University of Oulu

Mira Heinonen                            2011              Ph.D.              cell/ molecular biology, University of Helsinki

Johanna Eriksson              2014              Ph.D.              cell/ molecular biology, University of Helsinki

Official examiner of doctoral dissertations (Opponent)

 

Name              Date               Degree              Field of study/University             

Soheil Naderi              1999              Ph.D.              cell/molecular biology, University of Oslo, Norway

Jonas Fuxe              2001              Ph.D.              cell/molecular biology, Karolinska Institute, Sweden

Song-Ping Li              2003              Ph.D.              cell/molecular biology, University of Turku, Finland

Katerina Pardali              2005              Ph.D.              cell/molecular biology, University of Uppsala, Sweden

Marie Simonsson              2007              Ph.D.              cell/molecular biology, University of Uppsala, Sweden

Adam Ciesiolka              2015              Ph.D.              biochemistry, University of Dundee, United Kingdom

 

Referee for docenture promotion

 

Name              Date               Degree              Field of study/University             

Tomi Mäkelä              1996              M.D., Ph.D.              cell/molecular biology, University of Helsinki

Marianne Tiainen               2003              Ph.D.              cell/molecular biology, University of Helsinki

Nina Nupponen               2006              Ph.D.              cell/molecular biology, University of Helsinki

 

Referee for professorial academic promotions

Associate Professor promotion evaluation 2013, 2017, Johns Hopkins University SOM

Associate Professor promotion evaluation 2015, Roswell Park Cancer Institute, NY

Professor in Molecular Cancer Pharmacology 2015, Karolinska Institutet, Sweden

Professor promotion evaluation 2016, University of Alabama Birmingham, AL

Professor in Cancer Research 2019, University of Turku, Finland

 

 

Educational Program Building/Leadership

 

1994-00               Member, Helsinki Graduate School in Biotechnology Planning and Examination Board

2003,2006               Ad Hoc Reviewer, Helsinki Biomedical Graduate School

2007                            Member, Doctoral Program Steering Committee Karolinska Institute-University of Helsinki

 

Graduate Program Member

 

1999-2014               Helsinki Biomedical Graduate School, University of Helsinki

2008-               Member, Graduate Program in Cellular and Molecular Medicine, Johns Hopkins University

2009-               Member, Graduate Program in Pathobiology, Johns Hopkins University

2016-              Member, Graduate Program in Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health

2018-               Doctoral Program in Drug Research, University of Helsinki

 

RESEARCH ACTIVITIES

 

Research Program Building / Leadership

 

2006-6/2007              Director, Molecular Cancer Biology Program, University of Helsinki

2006-8/2007              Founder and Coordinator, Helsinki Functional Imaging Center, Helsinki

2007-               Director, Molecular Radiation Sciences Research Division, Radiation Oncology and Molecular Radiation Sciences

2017-              Vice Chair for Research, Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine

2019-               Co-Director, Chemical and Structural Biology Program, SKCCC

 

Inventions, Patents, Copyrights

  •                                                    Laiho M, Peltonen K. US 8,680,107; US 10,214,491; EU 2195316 (GB, FR, DE, ES, IT); EU 2889297 (GB, FR, DE, ES, IT, IR); Canada 2,691,227; Canada 2,912,456 “Activators and therapeutic applications thereof” 2016-2018. Total 6 granted patents.
  •                                                    Laiho M, Barrow JA, Colis L, Ernst G, Sanders S. PCT/US2015/021699/15765295/2,943,022 US, EU, Canada “Compounds which inhibit RNA polymerase, compositions including such compounds, and their use” 2014-. Total 3 pending patents.
  •                                                    Laiho M, Liu H, Sirajuddin P, Ikonen E. PCT/US2017/052863, 16/335,737, 2017330390, 17853955.7, US, Australia, Canada, Japan, EU “Combinatory treatment strategies of cancer based on RNA polymerase I inhibition” 2016-. Total 5 pending patents.
  •                                                    Shah AA, Casciola-Rosen L, Rosen A, Igusa T, Laiho M. PCT/US2018/047770 “Screening Method to Identify Scleroderma Immune Responses with Anti-cancer Activity, and Induction of such Immune Responses for Cancer Therapy”.

 

ORGANIZATIONAL ACTIVITIES

Institutional  Administrative Appointments

 

1993-1995              Member, Governing Board, Department of Virology, University of Helsinki

2006-2007              Director, Molecular Cancer Biology Program, University of Helsinki

2007                                          Member, Governing Board, Haartman Institute, University of Helsinki

2007-                             Director, Molecular Radiation Sciences, Radiation Oncology, JHU

2011-                             Executive, Finance, Clinical Trials and Educational Committees, Radiation Oncology and MRS, JHU

Faculty/University Administrative Appointments

 

1993-2000              Secretary, Biocentrum Helsinki Governing Board, University of Helsinki

2001                                          Member, Meilahti Campus Planning Working Group, University of Helsinki

2003                                          Member and Scientific Secretary, Acting Research Council, Faculty of Medicine, University of Helsinki

2004                                          Scientific Secretary, Research Council, Faculty of Medicine, University of Helsinki

2005-2007              Vice-Chair, Medicine Fund, Administrative Committee, University of Helsinki

2007                                          Member, Research Program Governing Board, University of Helsinki

2007                                          Member, Governing Board, Biocentrum Helsinki, University of Helsinki

2007                                          Member, University of Helsinki Colloquium

2011                                          Space Committee, Johns Hopkins University School of Medicine

2012-                                          SKCCC Research Council, Johns Hopkins University School of Medicine

2012-2016              Status of Women Committee, Johns Hopkins University School of Medicine

2014-                                          Research Council, Johns Hopkins University School of Medicine

2016-2018              TAG Therapeutics Committee, Member, Johns Hopkins University School of Medicine

2016-                                          SKCCC New Drug Discovery Committee, Member

2018-                                          Associate Professor Reappointment Review Committee, Member, Johns Hopkins University School of Medicine

 

Editorial Activities

 

Editorial Board appointments

Annals of Medicine 2002-2007

Prostate 2012-

Cancer Research 2016-2019

Journal of Clinical Investigation 2018-

 

Journal Peer Review Activities

BBA – Molecular Basis of Disease, Ad Hoc Reviewer

British Journal of Cancer, Ad Hoc Reviewer

Cancer Cell, Ad Hoc Reviewer

Cancer Chemical Biology, Ad Hoc Reviewer

Cancer Research, Ad Hoc Reviewer

Carcinogenesis, Ad Hoc Reviewer

Cell Death Differentiation, Ad Hoc Reviewer

Clinical Cancer Research, Ad Hoc Reviewer

DNA Repair, Ad Hoc Reviewer

Duodecim, Ad Hoc Reviewer

Endocrine-Related Cancer, Ad Hoc Reviewer

Experimental Cell Research, Ad Hoc Reviewer

FEBS Letters, Ad Hoc Reviewer

International Journal of Cancer, Ad Hoc Reviewer

International Journal of Radiation Biology, Ad Hoc Reviewer

Journal of Cell Biology, Ad Hoc Reviewer

Journal of Cell Science, Ad Hoc Reviewer

Journal of Clinical Investigation, Ad Hoc Reviewer

Journal of Endocrinology, Ad Hoc Reviewer

Journal of Medicinal Chemistry, Ad Hoc Reviewer

Molecular Cancer Therapeutics, Ad Hoc Reviewer

Molecular and Cellular Biology, Ad Hoc Reviewer

Molecular and Cellular Endocrinology, Ad Hoc Reviewer

Nature Reviews in Cancer, Ad Hoc Reviewer

Nature, Ad Hoc Reviewer

Nature Communications, Ad Hoc Reviewer

Nucleic Acids Research, Ad Hoc Reviewer

Oncogene, Ad Hoc Reviewer

PLoS Genetics, Ad Hoc Reviewer

Proceedings of National Academy of Sciences USA, Ad Hoc Reviewer

Science Signaling, Ad Hoc Reviewer

 

Advisory Committees, Review Groups

 

1995-1997               Secretary, MRC Steering Committee for Biotechnology and Molecular Biology,

                                          Academy of Finland

1998-2007              Ad Hoc reviewer, Medical Research Council, Academy of Finland

2002-2007              Member, Advisory Expert Group, National Agency for Medicines, Finland

2004                                          Ad Hoc reviewer, Austrian Science Fund, Austria

2004                                          Ad Hoc reviewer, Danish Cancer Society, Denmark

2004                                           Ad Hoc reviewer, Health Research Council of New Zealand

2004-2006              Ad Hoc reviewer, Wellcome Trust, London, UK

2005                                          Scientific Secretary, Evaluation of Technomedicum, University of Helsinki

2006                                          Ad Hoc reviewer, Norwegian Research Council, Norway

2006, 2018              Ad Hoc reviewer, Medical Research Council, UK

2006                                          Ad Hoc reviewer, LÒreal Foundation, Finland

2007                                          Ad Hoc reviewer, A*Star Biomedical Research Council, Singapore

2008, 2013,2015              Ad Hoc reviewer, European Research Council

2008, 2013              Ad Hoc reviewer, DoD, CDMRP

2009-                                          Ad Hoc reviewer, ASTRO abstract review committee

2009-                                          Ad Hoc reviewer, The Prostate Cancer Charity, UK

2010, 2017              Ad Hoc reviewer, Dutch Cancer Society, NL

2010, 2011              Ad Hoc reviewer, Cancer Research UK, UK

2012                                          Ad Hoc reviewer, French National Research Agency, FR

2012, 2014              Ad Hoc reviewer, Samsung Biomedical Research Institute, ROK

2013                                          Ad Hoc reviewer, Health Research Council of New Zealand, NZ

2013                                          Ad Hoc reviewer, AICR (Association for International Cancer Research), UK

2014, 2016,2018              Ad Hoc reviewer and panel member, DFG German Research Foundation, GER

2014, 2015              Ad Hoc reviewer, Israel Science Foundation, IL

2016                                          Ad Hoc reviewer, National Institutes of Aging, NIH

2016-                                          Ad Hoc reviewer, Prostate Cancer Foundation

2017, 2020              Ad Hoc reviewer, Harrington Discovery Institute

Conference Organizer

 

1997              Cell Proliferation and Differentiation, University of Helsinki, Finland. September 6-8, 1997. 

2000              Molecular and Cellular Targets in Cancer, University of Helsinki, Finland. September 1-2, 2000.

2002              Molecular Genesis of Cancer, Sigrid Jusélius Foundation Symposium, Espoo, Finland. June 6-9, 2002.

2004              6th NorFa p53 and Cell Cycle Workshop, Svartå, Finland. June 11-13, 2004.

2004              Molecular Mechanisms of Cancer, Biomedicum Helsinki, University of Helsinki, Finland. September 3, 2004.

2004              Imaging Technologies of Live Cells and Animals, Biomedicum Helsinki, University of

              Helsinki, Finland. November 1-2, 2004.

2006              Advanced  Technologies in Biological Imaging, Biomedicum Helsinki, University of

              Helsinki, Finland. October  26-31, 2006.

2007              Translating the Cancer Genome, Biomedicum Helsinki, University of Helsinki, Finland. August 30-31, 2007.

2009              DNA Damage Control – from Cancer to Therapeutics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD. May 8, 2009.

2010              Radiation Oncology and Molecular Radiation Sciences Scientific Retreat, Johns Hopkins University, Baltimore, MD. September 18, 2010.

2011              Radiation Oncology and Molecular Radiation Sciences Scientific Retreat, Johns Hopkins University, Baltimore, MD. September 17, 2011.

2012              Radiation Oncology and Molecular Radiation Sciences Scientific Retreat, Johns Hopkins University, Baltimore, MD. September 22, 2012.

2013              Radiation Oncology and Molecular Radiation Sciences Scientific Retreat, Johns Hopkins University, Baltimore, MD. October 19, 2013.

 

RECOGNITION

 

Awards, honors

 

1989                                           Duodecim (Finnish Medical Society Duodecim) Literary Award

1995                                           Duodecim (Finnish Medical Society Duodecim) Young Investigator Award

2000                                           Finnish Medical Foundation 40-year Celebration Award

2001                                           Institut des Sciences de la Santé Europe et Médecine Junior Prize

2003               Helsinki City Science Prize

2008                                          The Finnish Academy of Science and Letters, Member

2014                                          Prostate Cancer Foundation Global Challenge Award

2014                                          Harrington Scholar-Innovator Award

2016                                          Dean’s Distinguished Lecture 2016 Johns Hopkins University

 

Invited talks

 

1986              Nordic Cancer Union: Cancer Prevention: Basic and Practical, Espoo, Finland.

1987              IX Meeting of the European Association for Cancer Research, Helsinki, Finland. “Transforming growth factor-ß regulates the proteolytic activity of cultured normal and malignant cells”.

1990              BioBio Society on Signal transduction, Helsinki, Finland. October 12, 1990. “Action of the TGF-ß growth inhibitor”.

1991              Tampere Cancer Scientists, Finnish Cancer Institute and Finnish Society for Pathology, Microbiology and Virology on Molecular mechanisms of malignant growth, Tampere, Finland. May 2-4, 1991. “Receptors and signals of TGF-ß”.

1991              Biochemical Society in Oulu, Oulu, Finland. May 29, 1991. “TGF-ß receptors and growth regulatory mechanisms”.

1992              Finnish Cancer Organizations on Gynecological Malignomas, Helsinki, Finland. February 6-7, 1992. “Growth factors and Tumor suppressor genes”.

1992              ISD on Cellular Programmes for Growth, Differentiation, and Neoplasia, Helsinki, Finland. July 19-23, 1992. “Expression human RB in mouse fibroblasts: regulation by mouse cell factors and effects on cell growth”.

1998              Biocentrum Helsinki Summer Retreat, Haikko Manor, Finland. June 1-2, 1998. “Bypass of cell cycle breaks”.

1998              Lung Cancer Symposium, Saariselkä, Finland. American College of Chest Physicians. December 3-5, 1998. “p53 mechanisms and cell cycle checkpoints in lung cancer”.

1999              Nordic p53 Workshop, NorFA, Otepää, Estonia. June 11-13, 1999. “p53 in the control of cellular UV response”.

2000              Second p53/Cell Cycle Workshop, NorFA, Lejondals Slott, Sweden. June 9-11, 2000. “Regulation of cell cycle progression”.

2001              1st International MDM2 Workshop, Dundee, Scotland. September 15-18, 2001. “Inhibition of the proteasome causes MDM2 localization to nucleoli”.

2001              32nd Nordic Haematological Spring Meeting, Vaasa, Finland. May 9-12, 2001. “Cell cycle control and tumor suppressors in hematological malignancies”.

2003              Biocentrum Helsinki Annual Day, Helsinki, Finland. November 28, 2003. “DNA damage induced cell arrest/death responses”.

2004              First IEO-IFOM Meeting on Cancer, Milan, Italy. March 11-13, 2004. “NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation”.

2004              Detection and Consequences of p53 Mutations, Kuopio, Finland. July 16-17, 2004. “DNA damage invoked p53 pathways”.

2004              12th International p53 Workshop, Dunedin, New Zealand. November 6-10, 2004. “Stress induced changes in p53 interactions”.

2005              German Cancer Research Center, Heidelberg, Germany. December 6, 2005. “p53 and the nucleolar stress response”.

2005              Finnish Cancer Organisation XXXIII Symposium, Tuusula, Finland. Februry 10-11, 2005. “Molecular changes in cancer”.

2005              Ludwig Institute for Cancer Research, Uppsala, Sweden. September 26, 2005. Biomedical Center Seminar “p53 and the nucleolar stress response”.

2005              New Frontiers in Cancer Research and Therapy, Cancer Center Karolinska, Karolinska Institute, Sweden. March 10-11, 2005. “p53 and the nucleolar stress response”.

2005              Cellular responses to DNA damage, Benzon Symposium, Cøpenhagen, Denmark. August 22-25, 2005. “NPM and PML interact in DNA damaged cells”.

2006              4th EADV Spring Symposium, Saariselkä, Finland. February 9-12, 2006. “Pathways to melanoma and the DNA damage response”.

2006              7th Bergen International Cancer Conference, Bergen, Norway. May 12-13, 2006. “p53, NPM and PML in DNA damage response and cancer”.

2006              13th International p53 Workshop, New York, NY, USA. May 20-24, 2006. “Human prostate epithelia lack DNA damage-induced p53 response and checkpoint enforcement”.

2007              National Science Week, University of Helsinki, Finland. January 12, 2007. “Barriers against cancer”.

2007              Society of Obstetrics and Gynaecology, FinnMEDI, Tampere, Finland. March 16, 2007. “Aging and cellular senescence”.

2007              Ludwig Institute for Cancer Research, Uppsala, Sweden. March 29, 2007. “Switching on the p53 response in human cancers”.

2008              Third Annual Prostate Cancer Day, Baltimore, MD. February 9, 2009. “Radiation Oncology Prostate Cancer Overview”.

2008              3rd Baltimore Area Repair Symposium, Baltimore, MD. March 27, 2008. “Aberrant DNA damage checkpoint responses of the human prostate epithelium”.

2008              EMBO Workshop on Nucleolus, Leeds, UK. June 23-26, 2008. “Tumor suppression and the nucleolus”.

2008              14th International p53 Workshop, Shanghai, China. October 31, 2008. “Identification of novel p53 pathway activating small molecule compounds”.

2009              Fourth Annual Prostate Cancer Day, Baltimore, MD. February 7, 2009. “Utilization of Prostate Tissue Cultures in Determination of Cellular DNA Damage Response”.

2009              DNA Damage Control – from Cancer to Therapeutics, Baltimore, MD. May 8, 2009. “p53 activation in cancer therapies”.

2009              Finnish Society for Oncology Annual Radiotherapy Symposium, Helsinki, Finland. May 14-15, 2009. “DNA damage response and new therapeutic approaches”.

2009              2nd GENICA/CANGENIN Genomic instability Workshop, Athens, Greece. May 16-19, 2009. “Discovery of novel topoisomerase I inhibitors through high-content screen for p53 activators”.

2009               Danish Cancer Society, Copenhagen, Denmark. October 30, 2009. “p53, DNA topology and cell stress responses”.

2010              3rd GENICA/CANGENIN/NordForsk Genomic instability Workshop, Milan, Italy. November 20-23, 2010. “DNA Damage Recognition via Activated ATM Pathway in Non-proliferating Human Prostate Tissue”.

2011              ASTRO 53rd Annual Meeting, Miami, FL. October 2-6, 2011. “Differential epithelium DNA damage response to ATM and DNA-PK pathway inhibition in human prostate tissue culture”.

2011              4th NordForsk/CANGENIN Genomic instability Workshop, Zandvoort, Netherlands. September 30- October 2, 2011. “Nucleolus as a stress response center”.

2012              5th CANGENIN Genomic instability Workshop, Barcelona, Spain. April 15-17, 2012. “Novel targeting modality for destruction of RNA Polymerase I”.

2012              Wellcome Trust Conference on Subnuclear Structures and Disease, Cambridge, UK. June 28-30, 2012. “Novel Modality to Target RNA Polymerase I”.

2013              Cold Spring Harbor Laboratory Symposium on Cancer Biology and Therapeutics, Cold Spring Harbor, NY. April 23-27, 2013. “Novel Targeting Modality for Destruction of RNA Polymerase I”.

2013              3rd NordForsk Chromatin, Transcription and Cancer Meeting, Køpenhagen, Denmark. June 26-28, 2013. “Novel Modality to Target RNA Polymerase I”.

2013              Baltimore-Philadelphia Prostate Cancer Summit, Baltimore, MD. November 1, 2013. “Novel Modality to Target RNA Polymerase I”.

2014              6th Baltimore Area Repair Symposium, Baltimore, MD. March 7, 2014. “Ribosomal RNA transcription and therapeutic targeting”.

2014              Finnish Cancer Institute on Frontiers in Translational Cancer Research, Helsinki, Finland. June 9-10, 2014. “Ribosomal RNA Transcription and its Cancer Therapeutic Targeting”

2014              16th International p53 Workshop, Stockholm, Sweden. June 15-19, 2014. “Therapeutic Targeting of RNA Pol I”.

2014              International Conference on Transcription by RNA Polymerases I, III, IV, and V, Ann Arbor, Michigan. June 19-24, 2014. “Therapeutic Targeting of RNA Pol I”.

2014              4th NordForsk Chromatin, Transcription and Cancer Meeting, Hverageroi, Iceland. August 27-29, 2014. “RNA Polymerase I intervention therapies in cancer”.

2015              Eight Annual Prostate Cancer Program Retreat, Fort Lauderdale, FL. March 15-17, 2015. “Targeting RNA Polymerase I”.

2015              Harrington Discovery Institute 3rd Annual Scientific Symposium, Cleveland, OH. May 20-21, 2015. “A novel approach to treat cancer: RNA polymerase I inhibition”.

2016              International Conference on Transcription by RNA Polymerases I, III, IV, and V, Ann Arbor, Michigan. June 24-28, 2016. “Targeting of RNA Pol I activates a novel transcription elongation checkpoint”.

2017              ASBMB Special Symposia Series Emerging Roles for the Nucleolus, Kansas City, Missouri. October 26-29, 2017. “Targeting of RNA Pol I activates a novel transcription elongation checkpoint”.

2017               Prostate Cancer Research Day, Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD. December 7, 2017. “Lipids Meet RNA Production – a New Paradigm”.

2018              International Conference on Transcription by RNA Polymerases I, III, IV, and V, Toulouse, France. June 26-29, 2018. “Translation of small molecule inhibitors of RNA Pol I transcription as a therapeutic approach for cancer treatment”.

2019              Twelfth Annual Prostate Cancer Program Retreat, Fort Lauderdale, FL. March 3-5, 2019. “RNA Polymerase I and its therapeutic targeting”.

2019              ASBMB Special Symposia Series Emerging Roles for the Nucleolus, Kansas City, Missouri. October 24-27, 2019. “Therapeutic targeting of RNA Pol I in cancer”.

 

 

 

Research seminars

 

1991              Laakso Hospital, Helsinki, Finland. March 8, 1991. “Oncogenes and tumor suppressor genes”.

1991              Finnish Red Cross, Helsinki, Finland. December 4, 1991. “Transforming growth factor-ß control of cell growth and proteolysis”.

1992              Department of Clinical Chemistry, Helsinki University Central Hospital. March 6, 1992. “TGF-ß growth regulatory effects”.

1992              Department of Biochemistry, University of Helsinki, Finland. February 14, 1992. “Transforming growth factor-ß and the retinoblastoma gene product in growth control”.

1995               Department of Pathology, University of Helsinki, Finland. March 14, 1995. “Tumor suppressor genes and their action”.

1997              Turku Immunology Center, Turku, Finland. February 5, 1997. “p53 in DNA damage control and cell cycle”.

1998              Department of Clinical Chemistry, Helsinki University Central Hospital. March 13, 1998. “p53 tumor suppressor protein actions in the control of DNA damage and cell cycle”.

2000              AIVirtanen Institute, University of Kuopio, Kuopio, Finland. March 13, 2000. “Cell cycle control by growth factors”.

2000              Biocity Turku, Turku, Finland. November 8, 2000. “Growth factors in cell cycle control”.

2000               Department of Pathology, University of Helsinki, Finland. November 14, 2000. “Role of p53 pathway in tumor biology”.

2001              Department of Dermatology, Helsinki University Central Hospital, Helsinki, Finland. October 10, 2001. “Role of p53 in skin cancer”.

2002              Institute of Medical Technology, University of Tampere, Finland. March 13, 2002. “Transcriptional control by p53”.

2002              Developmental and Reproductive Biology Program, Biomedicum Helsinki, Finland. November 26, 2002. “UV damage induced transcriptional and cellular responses”. 

2003              Nordea Research Seminar in Biomedicine, Biomedicum Helsinki, Finland. September 23, 2003. “Genetic changes in cancer”.

2005              Biocity Turku, Turku, Finland. February 3, 2005. “p53 and the nucleolar stress response”.

2006              Drug Discovery and Development Center, University of Helsinki, Finland. November 7, 2006. “The p53 pathway as a therapeutic target”.

2007              Department of Urology, Helsinki University Central Hospital, Finland. February 2, 2007. “Prostate DNA damage responses”.

2007              Neurobiology Research Program, Biomedicum Helsinki, Finland. February 7, 2007. “DNA damage, cell senescence and cancer”.

2007              Department of Radiation Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD. April 23, 2007. “Switching on the p53 response in human cancers”.

2007              Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD. November 20, 2007. “DNA damage responses in the prostate”.

2008              Translational Research Conference, The Johns Hopkins University School of Medicine, Baltimore, MD. December 10, 2008. “p53 and DNA topology”.

2009              Biennial Meeting of The Johns Hopkins Medical and Surgical Association, The Johns Hopkins University School of Medicine, Baltimore, MD. June 5, 2009. “p53 Pathway in Cancer Therapy”.

2009              ICMIC Seminar Series, The Johns Hopkins University School of Medicine, Baltimore, MD. September 9, 2009. “Visualizing cell stress responses in organelles, cells and tissues”.

2010              Breast Cancer Research Program, SKCCC, The Johns Hopkins University School of Medicine, Baltimore, MD. January 12, 2010. “p53, DNA topology and cellular stress response”.

2010              IVth Quarter, SKCCC, The Johns Hopkins University School of Medicine, Baltimore, MD. April 12, 2010. “DNA damage pathways in cancer”.

2010              Department of Radiation Oncology, Grand Rounds, The Johns Hopkins University School of Medicine, Baltimore, MD. May 17, 2010. “Discovery of small-molecule compounds”.

2010              Chemical Therapeutics Research Program, SKCCC, The Johns Hopkins University School of Medicine, Baltimore, MD. May 17, 2010. “Discovery and mechanisms of novel small-molecule compounds”.

2010              Department of Urology, Stanford University, San Francisco, CA. November 4, 2010. “New insights into p53 pathway as a therapeutic target”.

2010              NYU Cancer Institute, New York University, New York, NY. December 15, 2010. “New insights into p53 pathway as a therapeutic target”.

2011              Chemical Therapeutics Research Program, SKCCC, The Johns Hopkins University School of Medicine, Baltimore, MD. June 15, 2010. “New insights into p53 pathway as a therapeutic target”.

2011              Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, MD. December 6, 2011 “DNA Damage Responses in Differentiated Tissues”.

2012              Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD. February 25, 2012. “Novel small-molecule regulators of androgen receptor activity in prostate cancer”.

2012              Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD. February 28, 2012. “Nucleolus as a stress response center”.

2012              Institute of Biotechnology, University of Helsinki, Helsinki, Finland. September 12, 2012. “Nucleolus as a stress response center”.

2012              Department of Molecular Biology and Genetics, The Johns Hopkins University School of Medicine, Baltimore, MD. October 18, 2012. “Nucleolus as a stress response center and therapeutic target”.

2012              Life Sciences Summit, New York, NY. December 13, 2012. “A novel anticancer compound”.

2013              Alliance for Science & Technology Development, Baltimore, MD. February 19, 2013. “A novel approach to treat cancer: RNA Polymerase I inhibition”.

2013              Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD. March 2, 2013. “RNA Polymerase I inhibition as a Strategy to Curb Prostate Cancer”.

2013              Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC. April 12, 2013. “The Nucleolus as a Stress Response Center and Therapeutic Target”.

2013              Cytostasis to Metastasis, Memorial Sloan-Kettering Cancer Center, New York, NY. April 26, 2013. “The Nucleolus as Therapeutic Target”.

2013              Biennial Meeting of The Johns Hopkins Medical and Surgical Association, The Johns Hopkins University School of Medicine, Baltimore, MD. June 7, 2013. “Novel Intervention Approaches to Treat Cancer”.

2013              Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD. September 11, 2013. “DNA damage – from signals to repair and back again”.

2014              Department of Biochemistry and Molecular Genetics/UAB Stem Cell Institute, University of Alabama, Birmingham, AL. August 18, 2014. “Ribosomal RNA Transcription and its Cancer Therapeutic Targeting”.

2014              University of Dundee, Scotland, UK.  September 9, 2014. “Therapeutic Targeting of RNA Polymerase I in Cancer”.

2014              Translational Research Conference, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD. September 24, 2014. “The Nucleolus, RNA Polymerase I and its Cancer Therapeutic Targeting”.

2015              Wednesday Seminars, National Institute of Aging, Baltimore, MD. March 11, 2015. “The Nucleolus, RNA Polymerase I and its Cancer Therapeutic Targeting”.

2015              Department of Radiation Oncology, Grand Rounds, The Johns Hopkins University School of Medicine, Baltimore, MD. July 21, 2015. “RNA Polymerase I and its Cancer Therapeutic Targeting”.

2016              The Johns Hopkins University School of Medicine, Baltimore, MD. May 4, 2016. Dean's Distinguished Lecture 2016: New Targets and New Molecules for Cancer: RNA Polymerase I Program”.

2016              Institute of Biotechnology Annual Retreat, University of Helsinki, Helsinki, Finland. May 19, 2016. “RNA Polymerase I Program”.

2016              BMB Training Program, School of Public Health, The Johns Hopkins University School of Medicine, Baltimore, MD. September 23, 2016. “New Targets and New Molecules for Cancer: RNA Polymerase I Program”.

2016              Molecular Radiation Sciences Progress Report Seminar, Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD. September 29, 2016. “Research reproducibility and rigor: Practices and practical examples”.

2017              Cancer Chemical and Structural Biology Program, The Johns Hopkins University School of Medicine, Baltimore, MD. January 24, 2017. “New Targets and New Molecules for Cancer: RNA Polymerase I Program”.

2017              Institute of Biotechnology, University of Helsinki, Helsinki, Finland. January 26, 2017. “RNA Polymerase I Program”.

2017              Biomedicum Helsinki Seminars, University of Helsinki, Helsinki, Finland. January 30, 2017. “RNA Polymerase I Program”.

2017              39th Biennial Meeting of The Johns Hopkins Medical and Surgical Association, The Johns Hopkins University School of Medicine, Baltimore, MD. June 8, 2017. “RNA Polymerase I Program – New Targets and New Molecules for Cancer”.

2017              Department of Clinical Pharmacology, The Johns Hopkins University School of Medicine, Baltimore, MD. September 20, 2017. “RNA Polymerase I and its Cancer Therapeutic Targeting”.

2018              Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD. February 14, 2018. “Biology and strategies to target RNA polymerase I in cancer”.

2018              Department of Biochemistry and Molecular Genetics Colloquim, University of Virginia, Charlottsville, VA. March 1, 2018. “RNA Polymerase I and its Therapeutic Targeting”.

2018              EMBL Blue Seminar, EMBL, Heidelberg, Germany. March 5, 2018. Biology and strategies to target RNA polymerase I in cancer”.

2018              Translational Research Conference, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD. October 17, 2018. “Biology and strategies to target RNA polymerase I in cancer”.

2018              Laval University, Quebec, Canada. October 12, 2018. Biology and strategies to target RNA polymerase I in cancer”.

2019              Department of Biophysics, The Johns Hopkins University School of Medicine, Baltimore, MD. October 16, 2019. “Biology and strategies to target RNA polymerase I in cancer”.

2020              IVth Quarter, SKCCC, The Johns Hopkins University School of Medicine, Baltimore, MD. March 16, 2020. “New Drug Discovery”.

2020              BMB Cancer Biology Course, The Johns Hopkins University School of Public Health, Baltimore, MD. May 6, 2020. “New Drug Discovery”.

 

 

 

 

Other Professional Accomplishments

 

Declared qualified for the following posts

 

1995              Professor of Cell Biology, University of Jyväskylä (ranked 2nd)

1998              Professor in Cancer Biology, University of Helsinki

2002              Research Professor in Cancer Biology, Finnish Cancer Institute (ranked 2nd)

2002              Professor in Biochemistry and Molecular Biology, University of Helsinki

2003              Professor in Molecular Biology, University of Helsinki (ranked 3rd)

2003              Professor in Cell and Tissue Biology, University of Helsinki

2004              Professor in Cell Biology, University of Jyväskylä (ranked 1st)

2006              Professor in Molecular Cancer Medicine, University of Helsinki

2007              K. Albin Johansson Professor in Cancer Biology, Finland (ranked 1st)

2008              Professor in Radiation Oncology and Oncology, Johns Hopkins University School of Medicine

              Page 1 of 27